share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Moore Matthew Richard

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Moore Matthew Richard

Arcutis Biotherapeutics | 4：持股變動聲明-高管 Moore Matthew Richard
美股sec公告 ·  05/04 04:33
牛牛AI助理已提取核心訊息
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, completed a sale of 4,681 shares of common stock on 05/02/2024. The shares were sold at a price of $8.7378 per share, resulting in a total transaction value of $40,901.64. This transaction followed an acquisition of 4,166 shares on 05/01/2024, which were granted at no cost. After these transactions, Moore holds a total of 145,505 shares in the company. The sale took place in the open market and is part of the normal course of insider transactions.
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, completed a sale of 4,681 shares of common stock on 05/02/2024. The shares were sold at a price of $8.7378 per share, resulting in a total transaction value of $40,901.64. This transaction followed an acquisition of 4,166 shares on 05/01/2024, which were granted at no cost. After these transactions, Moore holds a total of 145,505 shares in the company. The sale took place in the open market and is part of the normal course of insider transactions.
Arcutis Biotherapeutics高級副總裁兼首席商務官馬修·理查德·摩爾於2024年2月5日完成了4,681股普通股的出售。這些股票以每股8.7378美元的價格出售，總交易價值爲40,901.64美元。該交易是在2024年1月5日收購了4,166股股票之後進行的，這些股票是免費授予的。在這些交易之後，摩爾共持有該公司145,505股股份。此次出售是在公開市場上進行的，是內幕交易正常過程的一部分。
Arcutis Biotherapeutics高級副總裁兼首席商務官馬修·理查德·摩爾於2024年2月5日完成了4,681股普通股的出售。這些股票以每股8.7378美元的價格出售，總交易價值爲40,901.64美元。該交易是在2024年1月5日收購了4,166股股票之後進行的，這些股票是免費授予的。在這些交易之後，摩爾共持有該公司145,505股股份。此次出售是在公開市場上進行的，是內幕交易正常過程的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。